Expression of NY-ESO1 Protein in Multiple Myeloma
DOI:
https://doi.org/10.31584/psumj.2025276780คำสำคัญ:
immunohistochemistry, multiple myeloma, NY-ESO1, survivalบทคัดย่อ
Objective: To evaluate the proportion of New York esophageal squamous cell carcinoma 1 (NY-ESO1) protein expression, via immunohistochemistry staining in bone marrow of multiple myeloma patients. Additionally, to correlate the expression with clinical data and survival outcomes.
Material and Methods: The study population were multiple myeloma patients, diagnosed by bone marrow biopsy in Songklanagarind hospital; from 2012 and 2015. The clinical data and survival outcomes were collected. All cases were stained with NY-ESO1 (E978) antibody and interpreted by one pathologist and a resident.
Results: There were 61 patients that reached the criteria for this study. NY-ESO1 expression was detected in 4 of 61 cases (6.6%). The expression of NY-ESO1 was associated with serum albumin levels (p-value<0.01). However, no association between NY-ESO1 expression nor survival outcome was identified by survival analysis.
Conclusion: NY-ESO1 immunostaining showed low percentages of expression in multiple myeloma neoplastic cells, and was not associated with survival outcome.
เอกสารอ้างอิง
Röllig C, Knop S, Bornhäuser M. Multiple myeloma. The Lancet 2015;385:2197-208.
Cowan AJ, Allen C, Barac A, Basaleem H, Bensenor I, Curado MP, et al. Global burden of multiple myeloma: a systematic analysis for the global burden of disease study 2016. JAMA Oncol 2018.
Sureda A, Dreger P, Bishop MR, Kroger N, Porter DL. Prevention and treatment of relapse after stem cell transplantation in lymphoid malignancies. Bone Marrow Transplant 2018.
Rades D, Conde-Moreno AJ, Cacicedo J, Segedin B, Rudat V, Schild SE. Excellent outcomes after radiotherapy alone for malignant spinal cord compression from myeloma. Radiol Oncol 2016;50:337-40.
Tsang RW, Campbell BA, Goda JS, Kelsey CR, Kirova YM, Parikh RR, et al. Radiation therapy for solitary plasmacytoma and multiple myeloma: guidelines from the international lymphoma radiation oncology group. Int J Radiat Oncol Biol Phys 2018;101:794-808.
Vinay K, Abbas AK, Fausto N, Robbins SL, Cotran RS. Robbins and cotran pathologic basis of disease. In: Rinay K, editor. 9th ed. Philadelphia: Elsevier Saunders; 2015;p.310-2.
Abramson HN. The multiple myeloma drug pipeline-2018: a review of small molecules and their therapeutic targets. Clin Lymphoma Myeloma Leuk 2018;18:611-27.
Gerecke C, Fuhrmann S, Strifler S, Schmidt-Hieber M, Einsele H, Knop S. The diagnosis and treatment of multiple myeloma. Dtsch Arztebl Int 2016;113:470-6.
Kazandjian D, Ola L. A look backward and forward in the regulatory and treatment history of multiple myeloma: approval of novel-novel agents, new drug development, and longer patient survival. Seminars in Oncology 2016;43:682-9.
Lokhorst HM, Plesner T, Laubach JP, Nahi H, Gimsing P, Hansson M, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med 2015;373:1207-19.
Gjerstorff MF, Andersen MH, Ditzel HJ. Oncogenic cancer/testis antigens: prime candidates for immunotherapy. Oncotarget 2015;6:15772-87.
Baljevic M, Holstein SA. Present and future of immunotherapy in the management of multiple myeloma. J Oncol Pract 2018;14:403-10.
Fratta E, Coral S, Covre A, Parisi G, Colizzi F, Danielli R, et al. The biology of cancer testis antigens: putative function, regulation and therapeutic potential. Mol Oncol 2011;5:164-82.
Song X, Song W, Wang Y, Wang J, Li Y, Qian X, et al. MicroRNA-874 functions as a tumor suppressor by targeting cancer/testis antigen HCA587/MAGE-C2. J Cancer 2016;7:656-63.
Greve KB, Lindgreen JN, Terp MG, Pedersen CB, Schmidt S, Mollenhauer J, et al. Ectopic expression of cancer/testis antigen SSX2 induces DNA damage and promotes genomic instability. Mol Oncol 2015;9:437-49.
Por E, Byun HJ, Lee EJ, Lim JH, Jung SY, Park I, et al. The cancer/testis antigen CAGE with oncogenic potential stimulates cell proliferation by up-regulating cyclins D1 and E in an AP-1- and E2F-dependent manner. J Biol Chem 2010;285:14475-85.
Kim Y, Park D, Kim H, Choi M, Lee H, Lee YS, et al. miR-200b and cancer/testis antigen CAGE form a feedback loop to regulate the invasion and tumorigenic and angiogenic responses of a cancer cell line to microtubule-targeting drugs. J Biol Chem 2013;288:36502-18.
Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 2005;5:615-25.
Thomas R, Al-Khadairi G, Roelands J, Hendrickx W, Dermime S, Bedognetti D, et al. NY-ESO-1 based immunotherapy of cancer: current perspectives. Front Immunol 2018;9:947.
Chen YT. The journey from autologous typing to SEREX, NY-ESO-1, and cancer/testis antigens. Cancer Immun 2012;12:8.
Chen YT, Boyer AD, Viars CS, Tsang S, Old LJ, Arden KC. Genomic cloning and localization of CTAG, a gene encoding an autoimmunogenic cancer-testis antigen NY-ESO-1, to human chromosome Xq28. Cytogenet Cell Genet 1997;79:237-40.
Andrade VC, Vettore AL, Felix RS, Almeida MS, Carvalho F, Oliveira JS, et al. Prognostic impact of cancer/testis antigen expression in advanced stage multiple myeloma patients. Cancer Immun 2008;8:2.
Atanackovic D, Arfsten J, Cao Y, Gnjatic S, Schnieders F, Bartels K, et al. Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation. Blood 2007;109:1103-12.
Jungbluth AA, Ely S, DiLiberto M, Niesvizky R, Williamson B, Frosina D, et al. The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation. Blood 2005;106:167-74.
de Carvalho F, Vettore AL, Inaoka RJ, Karia B, Andrade VC, Gnjatic S, et al. Evaluation of LAGE-1 and NY-ESO-1 expression in multiple myeloma patients to explore possible benefits of their homology for immunotherapy. Cancer Immun 2011;11:1.
Schuberth PC, Jakka G, Jensen SM, Wadle A, Gautschi F, Haley D, et al. Effector memory and central memory NY-ESO-1-specific re-directed T cells for treatment of multiple myeloma. Gene Ther 2013;20:386-95.
Cronwright G, Le Blanc K, Gotherstrom C, Darcy P, Ehnman M, Brodin B. Cancer/testis antigen expression in human mesenchymal stem cells: down-regulation of SSX impairs cell migration and matrix metalloproteinase 2 expression. Cancer Res 2005;65:2207-15.
Cho HJ, Caballero OL, Gnjatic S, Andrade VC, Colleoni GW, Vettore AL, et al. Physical interaction of two cancer-testis antigens, MAGE-C1 (CT7) and NY-ESO-1 (CT6). Cancer Immun 2006;6:12.
Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev 2002;188:22-32.
Stockert E, Jager E, Chen YT, Scanlan MJ, Gout I, Karbach J, et al. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 1998;187:1349-54.
Kurashige T, Noguchi Y, Saika T, Ono T, Nagata Y, Jungbluth A, et al. Ny-ESO-1 expression and immunogenicity associated with transitional cell carcinoma: correlation with tumor grade. Cancer Res 2001;61:4671-4.
Luetkens T, Kobold S, Cao Y, Ristic M, Schilling G, Tams S, et al. Functional autoantibodies against SSX-2 and NY-ESO-1 in multiple myeloma patients after allogeneic stem cell transplantation. Cancer Immunol Immunother 2014;63:1151-62.
Liu JW, Lu X, Yang ZM, Deng LJ, Yang L. Immune effects of specific CTLs response induced by dendritic cells pulsed with NY-ESO-1 peptide. J Pecking Univ (Health Sci) 2017;49:840-6.
Jager E, Nagata Y, Gnjatic S, Wada H, Stockert E, Karbach J, et al. Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc Natl Acad Sci USA 2000;97:4760-5.
Napoletano C, Bellati F, Tarquini E, Tomao F, Taurino F, Spagnoli G, et al. MAGE-A and NY-ESO-1 expression in cervical cancer: prognostic factors and effects of chemotherapy. Am J Obstet Gynecol 2008;198:e1-7.
Szender JB, Papanicolau-Sengos A, Eng KH, Miliotto AJ, Lugade AA, Gnjatic S, et al. NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer. Gynecol Oncol 2017;145:420-5.
van Rhee F, Szmania SM, Zhan F, Gupta SK, Pomtree M, Lin P, et al. NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood 2005;105:3939-44.
Iura K, Kohashi K, Hotokebuchi Y, Ishii T, Maekawa A, Yamada Y, et al. Cancer-testis antigens PRAME and NY-ESO-1 correlate with tumour grade and poor prognosis in myxoid liposarcoma. J Pathol Clin Res 2015;1:144-59.
Li F, Zhao F, Li M, Pan M, SHi F. Decreasing New York esophageal squamous cell carcinoma 1 expressin inhibits multiple myeloma growth and osteolytic lesions. J Cell Physiol 2020;235:2183-94.
Kim EJ, Yoo C, Lee DH, Kim SW, Lee JS, Suh C. Serum albumin level is a significant prognostic factor reflecting disease severity in symptomatic multiple myeloma. Ann Hematol 2010;89:391–7.
ดาวน์โหลด
เผยแพร่แล้ว
รูปแบบการอ้างอิง
ฉบับ
ประเภทบทความ
สัญญาอนุญาต
ลิขสิทธิ์ (c) 2025 ผู้นิพนธ์และวารสาร
อนุญาตภายใต้เงื่อนไข Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
